Advanced Renal Cell Carcinoma drug, Temsirolimus, gets fast track status from FDA - 0 views
-
Matti Narkia on 06 Aug 09Wyeth Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted a new "fast track" designation for temsirolimus (CCI-779), an investigational mTOR kinase inhibitor, in the first-line treatment of poor-prognosis patients